Patents Assigned to BIOATLA, LLC
-
Publication number: 20170199198Abstract: A method of detecting tumor cells in a sample containing cells. In the method, a sample is encapsulated to produce a capsule with the sample encapsulated therein. The capsule containing the sample encapsulated therein is incubated under cell culture conditions suitable for supporting cell activity and growth of tumor cells and the encapsulated sample from the incubated capsule is contacted with a conditionally active antibody that has a higher binding affinity to a cell surface protein of a tumor cell under a first value of a condition of a tumor microenvironment, in comparison with the binding affinity of the conditionally active antibody to the same cell surface protein under a second value of the condition.Type: ApplicationFiled: January 11, 2017Publication date: July 13, 2017Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20170191055Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at some physiological conditions. For example, conditionally active biologic proteins are active in tumors, but virtually inactive at other body parts, or conditionally active antibodies cap able of crossing blood-brain-barrier.Type: ApplicationFiled: May 11, 2015Publication date: July 6, 2017Applicant: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 9637735Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: August 20, 2014Date of Patent: May 2, 2017Assignee: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 9637734Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: March 4, 2014Date of Patent: May 2, 2017Assignee: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20170044522Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Applicant: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 9464284Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: March 9, 2010Date of Patent: October 11, 2016Assignee: Bioatla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20160207989Abstract: This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof. A method for using the chimeric antigen receptor and cytotoxic cells for cancer treatment is also provided. A method for producing the chimeric antigen receptor is also provided.Type: ApplicationFiled: February 24, 2016Publication date: July 21, 2016Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20140378660Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: September 11, 2014Publication date: December 25, 2014Applicant: BioAtla LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20140356344Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Applicant: BioAtla LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 8859467Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: GrantFiled: July 16, 2010Date of Patent: October 14, 2014Assignee: Bioatla, LLCInventor: Jay Milton Short
-
Publication number: 20140187748Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: March 4, 2014Publication date: July 3, 2014Applicant: BIOATLA, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 8709755Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: GrantFiled: June 14, 2012Date of Patent: April 29, 2014Assignee: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20130303399Abstract: The disclosure provides a method for generation of humanized full length antibodies in mammalian cells. A library of humanized variants is provided with high, validated human framework diversity without requiring back-mutations to retain original affinity. Synthetic CDR encoding fragment libraries derived from a template antibody are ligated to human framework region encoding fragments from a human framework pool limited only to germline sequences from a functionally expressed anti-Combine bodies. The vector comprises a nucleic acid sequence encoding HC framework region 4. No CDR grafting or phage display is required.Type: ApplicationFiled: December 28, 2011Publication date: November 14, 2013Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20130281303Abstract: The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.Type: ApplicationFiled: December 28, 2011Publication date: October 24, 2013Applicant: BioAtla, LLCInventor: Jay M. Short
-
Publication number: 20130116125Abstract: The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.Type: ApplicationFiled: March 4, 2011Publication date: May 9, 2013Applicant: BIOATLA, LLCInventor: Jay M. Short
-
Publication number: 20120258865Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: June 14, 2012Publication date: October 11, 2012Applicant: BioAtla, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20120245036Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: ApplicationFiled: November 17, 2011Publication date: September 27, 2012Applicant: BIOATLA, LLCInventor: Jay Milton Short
-
Publication number: 20100260739Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: March 9, 2010Publication date: October 14, 2010Applicant: BIOATLA, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20100138945Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: November 13, 2009Publication date: June 3, 2010Applicant: BIOATLA, LLCInventors: Gerhard Frey, Hwai Wen Chang, Jay Short